• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
YANG Tongjiang,WANG Quanliang,XIE Lili,SHAN Yanqiang.Clinical application of Gefitinib[J].Journal Of Pharmaceutical Research,2017,36(4):243-245[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 3669times   Download 3603次 QR Code for this article
Scan with your phone!
吉非替尼的临床应用研究
杨同江,王全亮,解李丽,单衍强
Font:Larger+|Default|Smaller-
(齐鲁制药<海南>有限公司,海南 海口 570314)
摘要:
吉非替尼为靶向性表皮生长因子受体(EGFR)酪氨酸激酶抑制剂,2005年批准进口中国用于治疗局部晚期及或转移性非小细胞肺癌(NSCLC),其疗效好且血液系统不良反应较少,最常见的不良反应为腹泻和皮肤反应。2015年7月13日,美国FDA批准吉非替尼用于一线治疗转移性NSCLC患者一线治疗,针对用于EGFR基因突变的患者。本文主要综述其近年国内外的临床研究进展。
关键词:  吉非替尼  抗肿瘤  临床研究
DOI:10.13506/j.cnki.jpr.2017.04.015
基金项目:
Clinical application of Gefitinib
YANG Tongjiang,WANG Quanliang,XIE Lili,SHAN Yanqiang
(Qilu Pharmaceutical Co.,Ltd.,Haikou 570314, China)
Abstract:
Gefitinib is an EGFR inhibitor. It is only effective in cancers with mutated and overactive EGFR. The CFDA approved gefitinib in 2005 for non-small cell lung cancer (NSCLC). It was approved as monotherapy for the treatment of patients with locally advanced or metastatic NSCLC after failure of both platinum-based and docetaxel chemotherapies.On July 13,2015,FDA approved as a first-line treatment for NSCLC.The advancement of gefitinib in current clinic researches were reviewed in this article.
Key words:  Gefitinib  Anticancer  Clinical progress
Today's Visits:488    Total Visits:2383203
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.